Staff
Professor Brian Lipworth
Review Articles and Editorials
B1 LIPWORTH BJ, McDEVITT. Dose-Response Relationship with Bronchodilator Drugs. In Dose Response Relationships of Drugs (Ed: J Kuhlmann, W Wingender) W. Zuckschwerdt Verlag Munchen (1990), 119 - 125
B2 MOTWANI JG, LIPWORTH BJ. Clinical pharmacokinetics of drugs administered buccally and sublingually. Clinical Pharmacokinetics 1991; 21: 83-94 (Leading Article).
B3 LIPWORTH BJ. Risk versus benefits of inhaled -agonists in the management of asthma. Drug Safety 1992; 7: 54-70.
B4 LIPWORTH BJ, MCDEVITT DG. Inhaled 2-agonists in asthma: help or hindrance. British Journal of Clinical Pharmacology 1992; 33: 129-138.
B5 LIPWORTH BJ. Drugs for the treatment of airflow obstruction. Drug Information Notes 1992; 17: 5-14.
B6 LIPWORTH BJ. The -agonist controversy: fact or fiction? Clinical and Experimental Allergy 1992; 22: 659-664 (Editorial).
B7 LIPWORTH BJ. Clinical pharmacology of corticosteroids in bronchial asthma. Pharmacology and Therapeutics 1993; 58: 173-209.
B8 CARGILL RI, KIELY DG, LIPWORTH BJ. Hypoxaemia and the renin-angiotensin system: new answers for old questions. Pulmonary Pharmacology 1994; 7: 279-284.
B9 LIPWORTH BJ. New perspectives on inhaled drug delivery and systemic bioactivity. Thorax 1995; 50: 105-110 (Editorial).
B10 CARGILL RI, LIPWORTH BJ. The role of the renin-angiotensin and natriuretic peptide systems in the pulmonary vascular bed. British Journal of Clinical Pharmacology 1995; 40: 11-18.
B11 GROVE A, LIPWORTH BJ. Tolerance with 2-agonists: Time for reappraisal. British Journal of Clinical Pharmacology 1995; 39: 109-118.
B12 JACKSON CM, LIPWORTH BJ. Optimizing inhaled drug delivery in patients with asthma. British Journal of General Practice 1995; 45: 683-687.
B13 LIPWORTH BJ. Efficacy - safety evaluation of inhaled corticosteroids. Therapiewoche 1996; 21: 1194-1198.
B14 LIPWORTH BJ. Clinical pharmacology of 3-adrenoceptors. British Journal of Clinical Pharmacology 1996; 42: 291-300.
B15 LIPWORTH BJ. Airway and systemic effects of inhaled corticosteroids in asthma: dose response relationship. Pulmonary Pharmacology 1996; 9: 19-27.
B16 CLARK DJ, LIPWORTH BJ. Dose-response of inhaled drugs in asthma: An update. Clinical Pharmacokinetics 1997; 32: 58-74.
B17 LIPWORTH BJ. Pharmacokinetics of inhaled drugs. British Journal of Clinical Pharmacology 1996; 42: 697-705.
B18 LIPWORTH BJ, GROVE A. Evaluation of partial -adrenoceptor agonist activity. British Journal of Clinical Pharmacology 1997; 43: 9-14.
B19 LIPWORTH BJ. Airway subsensitivity with long-acting 2-agonists: Is there cause for concern? Drug Safety 1997; 16: 295-308. (Leading Article).
B20 LIPWORTH BJ, SECKL JR. Measures for detecting systemic bioactivity with inhaled and intranasal corticosteroids. Thorax 1997; 52: 476-482.
B21 LIPWORTH BJ. Treatment of acute asthma. Lancet 1997; 350 (Suppl II): 18-23.
B22 LIPWORTH BJ. Tolerance with ß2-Agonists - A clinical problem? In Lung Biology and Disease (Ed: Romain Pauwels, Paul M O'Byrne), Marcel Dekker Inc., New York (1997) Chapter 14;106:349-365
B23 LIPWORTH BJ. 2-adrenoceptor responsiveness and asthma activity. Clinical and Experimental Allergy 1998; 28: 257-260.
B24 LIPWORTH BJ. Modern drug treatment of chronic asthma. British Medical Journal 1999; 318: 380-384.
B25 LIPWORTH BJ, WILSON AM. Dose response to inhaled corticosteroids: benefits and risks. Seminars in Respiratory and Critical Care Medicine 1998; 19: 625-646.
B26 LIPWORTH BJ. The emerging role of leukotriene antagonists in asthma therapy. Chest 1999; 115: 313-316.
B27 LIPWORTH BJ. Leukotriene-receptor antagonists. Lancet 1999; 353: 57-62.
B28 LIPWORTH BJ. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Archives of Internal Medicine 1999; 159: 941-955.
B29 LIPWORTH BJ. Therapeutic implications for non-genomic glucocorticoid activity. Lancet 2000; 356: 87-89.
B30 LIPWORTH BJ, JACKSON CM. Safety of inhaled and intranasal corticosteroids: lessons for the new millennium. Drug Safety 2000; 23: 11-33.
B31 LIPWORTH BJ, WHITE P. Allergic inflammation in the unified airway: start with the nose. Thorax 2000; 55: 878-881.
B32 LIPWORTH BJ. Targets for inhaled treatment. Respiratory Medicine 2000; 94 (Supplement D), S13-D16.
B33 LIPWORTH BJ. The comparative safety/efficacy ratio of HFA-BDP. Respiratory Medicine 2000; 94 (Supplement D), S21-S26.
B34 LIPWORTH BJ. Budesonide/formoterol combination - a viewpoint. Drugs 2001; 61: 79-80.
B35 LIPWORTH BJ. Revisiting interactions between hypoxaemia and B2 agonists in asthma. Thorax 2001; 56:506-507.
B36 LIPWORTH BJ. Emerging role of anti-leukotriene therapy in allergic rhinitis. Clinical and Experimental Allergy 2001, 31: 1813-1821.
B37 LIPWORTH BJ. Optimizing bronchodilator therapy for COPD. Chest 2001, 119: 1628-1630.
B38 LIPWORTH BJ. Adrenal suppression with inhaled corticosteroids. Annals of Allergy, Asthma & Immunology 2001, 87: 359-361.
B39 LIPWORTH BJ. The role of long-acting -agonists in patients uncontrolled on inhaled steroids alone - a pharmacological approach. Clinical and Experimental Allergy 2001; 1: 23-28.
B40 LIPWORTH BJ. Antagonism of long-acting 2-adrenoceptor agonism. Br J Clin Pharmacol 2002; 54: 231-245
B41 LIPWORTH BJ, JACKSON CM. Second-line controller therapy for persistent asthma uncontrolled on inhaled corticosteroids. Drugs 2002; 62(16):2315-2332
B42 LEE DKC, GRAY RD, LIPWORTH BJ. Adenosine monophosphate bronchial provocation and the actions of asthma therapy. Clinical and Experimental Allergy 2003; 33: 287-294
B43 GRAY RD, LIPWORTH BJ. The GP's role in allergic rhinitis. Practitioner 2003;247:418-423
B44 CURRIE GP, FOWLER SJ, LIPWORTH BJ. Dose response of inhaled corticosteroids on bronchial hyperresponsiveness: a meta-analysis. Annals of Allergy, Asthma and Immunology 2003; 90:194-198.
B45 JACKSON CM, LIPWORTH BJ. Benefit-Risk Assessment of Long Acting ß2-Agonists in Asthma. Drug Safety 2004;27:243-270
B46 JACKSON CM, LIPWORTH BJ. Combined mediator antagonism for allergic rhinitis. Allergy 2004;59:276-279
B47 CURRIE GP, JACKSON CM, LIPWORTH BJ. Does bronchial hyperresponsiveness in asthma matter? Journal of Asthma 2004;41:247-258
B48 LIPWORTH BJ. Phosphodiesterase-4 inhibitor for asthma and chronic obstructive pulmonary disease. The Lancet 2005;365:167-175
B49 BUTTGEREIT F, BURMESTER GR, LIPWORTH BJ. Optimised glucocorticoid therapy: the sharpening of and old spear. Lancet 2005;365:801-803
B50 LIPWORTH BJ. Designer Inhaled Corticosteroids - Are They Any Safer? Chest 2005;128:10811084
B51 LIPWORTH BJ. Pharmacological interventions and outcome measurements in the unified airway. Clinical and Experimental Allergy 2005;5:26-31
B52 LIPWORTH BJ. Phosphodiesterase type 4 inhibitors for asthma: a real breakthrough or just expensive theophylline? Annals of Allergy, Asthma and Immunology 2006;96:640-642
B53 MENZIES D, NAIR A, LIPWORTH BJ. Non-invasive measurement of airway inflammation in asthma. J Asthma 2006:43;407-415
B54 CURRIE GP, LEE DKC, LIPWORTH BJ. Long-acting ß2-agonists in asthma. Not so SMART? Drug Safety 2006;647-656
B55 BOUSQUET J, CAUWENBERGE P van, KHALED N. Ait, BACHERT C, BAENA-CAGNANI CE, BOUCHARD J. BUNNAG C, CANONICA GW, CARLSEN KH, CHEN YZ, CRUZ AA, CUSTOVIC A, DEMOLY P, DUBAKIENE R, DURHAM S, FOKKENS W, HOWARTH P, KEMP J, KOWALSKI KL, KVEDARIENE V, LIPWORTH BJ, LOCKEY R, LUND V, MAVALE-MANUEL S, MELTZER EO, MULLOL J, NACLERIO R, NEKAM K, OHTA K, PAPADOPOULOS N, PASSALACQUA G, PAWANKAR R, POPOV T, POTTER P, PRICE D, SCADDING G, SIMONS FER, SPICAK V, VALOVIRTA E, WANG DY, YAWN B, YUSUF O. Pharmacologic and anti-IgE treatment of allergic rhinitis ARIA update (in collaboration with GA2LEN) Allergy 2006:61;1086-1096
B56 CURRIE GP, LIPWORTH BJ. Pharmacological management - inhaled treatment. Brit Med J 2006;332:1439-1441
B57 CURRIE GP, LEE DKC, LIPWORTH BJ. Pharmacological management - oral treatment. Brit Med J 2006:332;1497-1499
B58 LIPWORTH BJ. Long-acting beta 2 adrenoceptor agonists: a smart choice for asthma? Trends Pharmacol Sci 2007;28:257-262
B59 BOUSQUET J, KHALTAEV N, CRUZ AA, DENBURG J, FOKKENS WJ, TOGIAS A, ZUBERBIER T, BAENA-CAGNANI CE, CANONICA GW, VAN WEEL C, AGACHE I, AÏT-KHALED N, BACHERT C, BLAISS MS, BONINI S, BOULET LP, BOUSQUET PJ, CAMARGOS P, CARLSEN KH, CHEN Y, CUSTOVIC A, DAHL R, DEMOLY P, DOUAGUI H, DURHAM SR, VAN WIJK RG, KALAYCI O, KALINER MA, KIM YY, KOWALSKI ML, KUNA P, LE LT, LEMIERE C, LI J, LOCKEY RF, MAVALE-MANUEL S, MELTZER EO, MOHAMMAD Y, MULLOL J, NACLERIO R, O'HEHIR RE, OHTA K, OUEDRAOGO S, PALKONEN S, PAPADOPOULOS N, PASSALACQUA G, PAWANKAR R, POPOV TA, RABE KF, ROSADO-PINTO J, SCADDING GK, SIMONS FE, TOSKALA E, VALOVIRTA E, VAN CAUWENBERGE P, WANG DY, WICKMAN M, YAWN BP, YORGANCIOGLU A, YUSUF OM, ZAR H, ANNESI-MAESANO I, BATEMAN ED, BEN KHEDER A, BOAKYE DA, BOUCHARD J, BURNEY P, BUSSE WW, CHAN-YEUNG M, CHAVANNES NH, CHUCHALIN A, DOLEN WK, EMUZYTE R, GROUSE L, HUMBERT M, JACKSON C, JOHNSTON SL, KEITH PK, KEMP JP, KLOSSEK JM, LARENAS-LINNEMANN D, LIPWORTH B, MALO JL, MARSHALL GD, NASPITZ C, NEKAM K, NIGGEMANN B, NIZANKOWSKA-MOGILNICKA E, OKAMOTO Y, ORRU MP, POTTER P, PRICE D, STOLOFF SW, VANDENPLAS O, VIEGI G, WILLIAMS D; WORLD HEALTH ORGANIZATION; GA(2)LEN; ALLERGEN. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63:8-160
B60 LIPWORTH BJ, WILLIAMSON PA. Beta-Blockers for Asthma: a Double Edged Sword. The Lancet 2009;373:104-105
B61 BUTTGEREIT F, BURMESTER GR, LIPWORTH BJ. Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol 2009;5:18-19
